SAGE PRO

Home / Research / Dr. Reddy's Laboratories Limited

SAGE PRO · ORIGINAL EQUITY RESEARCH

Dr. Reddy's Laboratories Limited — Q2 FY27 Results Analysis

Underlying growth, reported sales decline

Published · Quarter Q2 FY27 · DRREDDY

Revenue₹8,671cr
EBITDA margin20.6%
Net cash₹2,502cr
COMPANY-SPECIFIC GRAPHICAL SUMMARY

What the reported figures reveal

CHART 1

Reported quarter performance vs last year

Revenue-1.5 % YoY
EBITDA-24 % YoY
PAT-36 % YoY

https://www.bseindia.com/xml-data/corpfiling/AttachHis/3787a62c-6056-45bf-a566-3851ca03f88c.pdf

CHART 2

Q2 FY27 IFRS financials

Revenue₹8,671 crore
EBITDA₹1,783 crore
PBT₹1,228 crore
PAT attributable₹925 crore

https://www.bseindia.com/xml-data/corpfiling/AttachHis/3787a62c-6056-45bf-a566-3851ca03f88c.pdf

CHART 3

Profitability margins in Q2

Gross52.1 % of revenue
EBITDA20.6 % of revenue
PBT14.2 % of revenue
PAT10.7 % of revenue

https://www.bseindia.com/xml-data/corpfiling/AttachHis/3787a62c-6056-45bf-a566-3851ca03f88c.pdf

CHART 4

Major disclosed spending

SG&A₹2,808 crore
R&D₹524 crore

https://www.bseindia.com/xml-data/corpfiling/AttachHis/3787a62c-6056-45bf-a566-3851ca03f88c.pdf

ORIGINAL RESEARCH INSIGHTS

Investment findings and watch points

RESEARCH INSIGHT

Underlying growth, reported sales decline

Consolidated revenue -1.5% YoY despite double-digit business growth excluding North American lenalidomide.

Watch: WATCH — normalize the post-lenalidomide earnings base.

RESEARCH INSIGHT

The reported EBITDA margin is 20.6%

Prior-quarter semaglutide inventory provisions distort sequential improvement.

Watch: Separate API remediation from recurring margin.

RESEARCH INSIGHT

Sequential recovery, still below prior year

Gross margin gained 562 bps sequentially but remained 254 bps below Q2 FY26.

Watch: Track product-mix and remediation effects.

RESEARCH INSIGHT

R&D is a continuing requirement

Q2 R&D spend of ₹524cr, about 6% of reported revenue.

Watch: Assess future launch output against spending.

FULL PUBLISHED RESEARCH

Earnings and management commentary analysis

SAGE PRO | Q2 FY2027, quarter ended 30 September 2026 | 17 November 2026 | NSE: DRREDDY Research stance: WATCH — underlying product momentum is encouraging, but the decline in lenalidomide and execution risks matter. This is a seven-chapter company-specific investor report, built from the already accepted October 2026 issuer presentation and earnings-call evidence. Figures are consolidated IFRS and ₹ crore unless stated otherwise.

30-second investment take

What is working. Excluding North American lenalidomide, the company described double-digit growth in its underlying businesses, supported by product launches in India, North America and emerging markets. Q2 FY27 revenue was ₹8,671 crore, up approximately 7% sequentially, but down 1.5% year-on-year. EBITDA was ₹1,783 crore, a 20.6% margin.

Key takeaways

  • What is risky. Reported growth continues to absorb the decline in the high-margin lenalidomide franchise.
  • Semaglutide API-related quality issues affected the preceding quarter, and manufacturing inspection observations must be resolved.
  • The stronger sequential EBITDA comparison therefore partly reflects recovery from an unusually weak Q1, not only sustainable operating improvements.

What the valuation demands. A defensible valuation requires the sustainable post-lenalidomide profit base, regulatory execution, biosimilar/product economics and a current price reference. No unverified numerical target is published.

Fact-labelled quarterly snapshot

Issuer-reported Q2 FY27 measureFigureComparison or basis
Consolidated revenue₹8,671 crore-1.5% YoY, approximately +7.4% QoQ
EBITDA incl. other income₹1,783 croreMargin 20.6%, -24% YoY, +77% QoQ
Profit before tax₹1,228 croreMargin 14.2%, -33% YoY, +122% QoQ
PAT attributable to equity shareholders₹925 croreMargin 10.7%, -36% YoY, +109% QoQ
Gross profit margin52.1%+562 bps QoQ, -254 bps YoY
R&D expense₹524 croreApproximately 6% of revenue
SG&A₹2,808 croreApproximately 32% of revenue
Quarter capex cash outflow₹186 croreManagement call figure
Net cash surplus, 30 Sep 2026₹2,502 croreManagement-reported, not enterprise valuation

Why it matters: The contrast between a declining reported YoY P&L and growing underlying business is the central research question. Model both rather than treating the adjusted base as reported results.

---

01 — The investment thesis: replacement growth must be profitable, not just fast

Dr. Reddy's is transitioning away from exceptional revenues on certain North American generic products toward a broader portfolio of branded generics, complex generics, biosimilars, new partnerships and CDMO services. The logic is attractive: success across more molecules and markets would reduce dependence on a single unusually profitable asset. But volume growth in replacement products can have lower margins, greater regulatory risk or higher development expenditure.

Key takeaways

  • The company identified a 1.5% fall in reported revenue even as the underlying base excluding North American lenalidomide grew at double-digit rates.
  • This is a useful distinction, not a reason to discard the reported decline.
  • If the legacy product generated unusually high contribution margins, replacing its sales does not automatically replace its cash earnings.

Bull hypothesis: India, emerging markets, new North American products and selected complex generics grow fast enough to absorb lenalidomide's fade while efficiencies stabilize gross margin.

Counter-hypothesis: The company wins revenue in new therapies but lower contribution per sale, generic pricing competition and regulatory remediation absorb returns.

The key analytical question is whether every rupee of replacement revenue can generate an appropriate return after R&D, regulatory costs, manufacturing investment and working capital. As of Q2 FY27, the report documents an encouraging commercial pipeline but does not assume every announced launch reaches scale.

Next observable proof: ongoing revenue and margin excluding lenalidomide, product-level approvals versus commercial launches, India growth on a comparable basis, and normalized operating cash conversion.

---

02 — What the financials actually say

The 23 October 2026 Q2 presentation is explicit: consolidated revenue was ₹8,671 crore, 1.5% below the year-earlier period but about 7% higher sequentially. EBITDA including other income reached ₹1,783 crore at a 20.6% margin; attributable PAT was ₹925 crore at 10.7%. These are the reported IFRS-group quarter figures; they are not a nine-month run rate.

Key takeaways

  • The financial contrast is pronounced.
  • EBITDA declined roughly 24% YoY and PAT roughly 36% YoY despite solid base-business growth.
  • A stronger sequential quarter should not erase the YoY deterioration.

Q1 FY27 also carried about ₹240 crore of inventory and related provisions connected with semaglutide API issues. That makes Q1 a poor clean denominator for evaluating underlying momentum.

The CFO described a 52.1% consolidated gross profit margin, up 562 basis points sequentially and down 254 basis points from Q2 FY26. The year-on-year decline was linked mainly to lower lenalidomide sales; Q1 margins had also been affected by semaglutide-related inventory costs. The correct model should treat the product mix, one-off provisions and future replacement assets separately.

SG&A was ₹2,808 crore, or around 32% of revenues, reflecting personnel increments, FX and freight pressures. R&D was ₹524 crore, or 6% of revenues, 16% below the year-earlier quarter. A lower R&D burden supports near-term margin but should not be treated as permanent savings if the development pipeline must be replenished.

Why it matters: Any investment forecast must independently consider the loss of a high-margin North American product, the durability of core growth, the treatment of API remediation costs and the medium-term R&D burden. A simple revenue CAGR applied to the current EBITDA margin is insufficient.

---

03 — Geography and product mix: diversified growth with very different economics

North America. The presentation identifies ₹2,489 crore of North American global-generics revenue for Q2 FY27 and a significant reported YoY drag as lenalidomide sales step down. Management said the underlying business excluding lenalidomide grew in double digits. North American generic competition can compress selling prices rapidly, and approval-driven launches make revenue uneven. Watch the launch cadence, price erosion, share sustainability and treatment of product-specific provisions.

Key takeaways

  • Europe. Reported regional revenue was ₹1,393 crore in Q2 FY27.
  • Management signalled more mixed growth in Europe than in several other markets.
  • The region should be evaluated on local pricing, tender exposure and currency translation, not directly compared with the North American product-margin mix.

India. The business is a strategic base for the company and a potential launch market for partnered vaccines and biosimilars. Management reported progress on product partnerships including the Takeda dengue vaccine, with a planned private-market introduction in H1 calendar 2027. This is a dated commercial ambition, not Q2 realized vaccine revenue.

Emerging markets. The company described double-digit underlying expansion and approvals for generic semaglutide in multiple jurisdictions. Regulatory authorization, market access and supply execution are separate steps; approvals alone do not establish contribution margin or market share.

CDMO / Aurigene. The presentation notes Aurigene Pharmaceutical Services passing US$100 million in revenue over the 12 months ending September 2026. A 12-month revenue threshold is not a quarterly consolidated-profit contribution. Contract mix, customer concentration, capital intensity and profitability require separate evidence.

Why it matters: The replacement portfolio is better diversified than a single high-margin molecule but may be less profitable per unit of revenue. Sustainable cash generation, rather than the count of product launches, should settle the thesis.

---

04 — Cash, capital and financial flexibility

The CFO reported ₹14,650 crore of operating working capital at 30 September 2026, approximately ₹297 crore above the June date. Working-capital growth can accompany geographic expansion and inventory requirements, but poor inventory turnover can also trap cash.

Key takeaways

  • Quarterly capex cash outflow was ₹186 crore, and the CFO described quarterly cash flow of ₹171 crore.
  • These are management's stated cash figures.
  • They should not be reclassified as independently audited free cash flow without reconciling the underlying definitions and financing flows.

Dr. Reddy's reported a ₹2,502 crore net cash surplus at quarter-end. That supports financing flexibility for launches, remediation and development, but there is no basis here for adding the entire figure to a valuation without considering the enterprise balance-sheet bridge, working capital and capital deployment.

The call also discussed foreign-currency hedge positions. Currency swings can affect reported margin and translation between rupees and foreign operations. A properly controlled comparison should separate local-currency sales, forex effects and customer pricing where the company discloses them.

Investment implication: Net cash is a useful buffer against product and remediation uncertainty, not evidence that the future pipeline will be self-funding at any rate of spend. Monitor working capital, capex, cash flow definitions, cash tied in product launches and unforeseen regulatory expenses.

---

05 — Management execution: approvals are positive, commercialization is the test

In its October call and Q2 presentation, management reiterated a long-term focus on double-digit underlying growth and sustainable margins. These objectives are directional, not the same as a guarantee of reported double-digit revenue growth during lenalidomide runoff.

Key takeaways

  • Semaglutide. The prior-quarter API issue caused inventory and related provisions; management said it was working to resolve the issue and expected renewed launch activity conditional on validation.
  • In a regulated manufacturer, remediation, regulator approval, production qualification, shipments and realized margins are distinct milestones.
  • The report does not declare the issue resolved without an accepted subsequent company update.

Biosimilars. The company reported a USFDA approval for a rituximab biosimilar and an India launch of a nivolumab biosimilar. These are strategically important but commercialization will depend on channel access, contracts, production and economics. Pipeline valuation should not treat approval as full market penetration.

Partnerships. Takeda's dengue-vaccine partnership, Gilead's HIV-prevention collaboration and other assets expand strategic optionality. Timelines and economics are uneven; an agreement, expected launch and realized cash earnings are not equivalent.

Quality and manufacturing. The presentation includes Form 483 observations across facilities and follow-up responses. These are genuine execution risks, not trivial administrative footnotes. Track closure status and any capacity or product supply effects before underwriting recovery.

Analyst questions and response themes. Management faced questions about profitability normalization, U.S. product dynamics, regulatory issues and the development portfolio. The investment-relevant response is the distinction between underlying commercial strength and actual reported EBITDA or cash realization; neither bullish commentary nor the count of regulatory filings substitutes for observed results.

Next-quarter dashboard: regulatory follow-up, semaglutide commercial recovery, lenalidomide decline, geographic margin mix, working-capital conversion and actual biosimilar shipments.

---

06 — Risk register and operating scenarios

RiskMechanismWatch
Lenalidomide declineReduction of an exceptional higher-margin revenue streamReported North America revenue and product-mix-driven gross margin
Pricing erosionGeneric drug competition can overwhelm volume growthRealized price/mix and local-currency growth
Quality remediationBatch or site issues lead to write-offs, cost and launch delaysClosure/response on manufacturing observations
Launch executionApprovals do not guarantee scalable market accessShipments, contracts and real contribution profit
R&D productivityDevelopment expenditure may not monetizePipeline stage, R&D spend and eventual launches
Working-capital demandsInventory or receivables absorb cashWorking capital, cash conversion and capex
FX and geographyRupee translation and different market marginsConstant-currency trends and regional contribution

Key takeaways

  • Bull case (operating): base-business growth broadens across markets, API remediation is resolved, complex products commercialize and gross margin recovers from the lenalidomide reset.
  • Working capital and R&D remain disciplined.

Base case: core sales grow but reported earnings remain restrained by lower legacy-product contribution, uneven geography and ongoing development investment. Sequential improvement occurs without a rapid return to the prior year's profit mix.

Bear case: regulatory issues persist, newer launches miss revenue or margin targets, lenalidomide falls faster than replacement profits ramp, and inventory or pricing losses weaken cash conversion.

These are conditional operating cases, not ₹/share valuations. We do not invent a fair value or peer multiple without comparable and dated inputs. The risks are important regardless of the headline AI score.

What breaks the constructive thesis: sustained reported gross margin weakness, deterioration in net cash, persistent unresolved quality observations, or replacement sales failing to produce positive incremental profit.

---

07 — Research decisions, source ledger and glossary

What to verify next. Prioritize the next quarter's reported IFRS group P&L over a selective adjusted base. Separately record North American lenalidomide runoff and growth in the remaining North American portfolio. Compare the gross margin to Q2's 52.1% and preserve the difference between EBITDA with other income and earnings before tax.

Key takeaways

  • Cash is the second test. Revisit working capital from the ₹14,650 crore September baseline, reported capex of ₹186 crore, stated quarterly cash flow of ₹171 crore and net cash surplus of ₹2,502 crore.
  • Seek matching disclosures to understand changes rather than making artificial assumptions.

Execution is the third test. Track manufacturing observations and their actual closures, semaglutide product shipments, approved biosimilar revenues and profitability, and partners' commercialization dates. The count of approvals without realized sales is not sufficient for valuation.

Source ledger — previously accepted issuer evidence

[1] Dr. Reddy's Q2 FY2027 investor presentation, issued 23 October 2026, document 11858, quarter ended 30 September 2026. It reports consolidated IFRS group figures and the product/region context. Original filing: https://www.bseindia.com/xml-data/corpfiling/AttachHis/3787a62c-6056-45bf-a566-3851ca03f88c.pdf.

[2] Dr. Reddy's Q2 FY2027 earnings conference call, held 23 October 2026, document 73675. The full original is stored and accepted for analysis within Sage PRO. Issuer link: The company's redistribution restrictions are respected here: analysis is paraphrased rather than reproducing the transcript.

Simple limitation: Based on company disclosures; uncertain future product earnings and valuation are not assumed.

Glossary. IFRS: international financial reporting standards. EBITDA: earnings before interest, tax, depreciation and amortization; here the issuer includes other income. API: active pharmaceutical ingredient. CDMO: contract development and manufacturing organization. YoY: versus the same quarter one year earlier. QoQ: versus the preceding quarter. Net cash surplus: management-defined net liquidity after specified borrowing offsets, not always free cash.

Bottom line: The underlying franchise appears healthier than the reported year-on-year revenue line suggests. Whether that merits a rerating depends on replacing lenalidomide contribution, resolving quality risks and turning launches into durable cash profits. No unsupported target is offered.

Additional company evidence

CHART 5

Q2 capex and reported cash flow

Capex outflow₹186 crore
Cash flow₹171 crore

https://www.bseindia.com/xml-data/corpfiling/AttachHis/3787a62c-6056-45bf-a566-3851ca03f88c.pdf

SOURCE REFERENCES

Original disclosures and investor presentations

  1. Dr Reddy's Laboratories Q2 FY27 investor presentation

Related research and comparisons

Other published Q2 FY27 reports

This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.